Delivery Order SPE2DR25D2212-SPE2DR26FB9PL
- Not listed
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for 80 mg Hysingla ER tablets, with a ceiling value of $1,531.57. The contract, which is not set-aside and employs firm fixed-price terms, was awarded on December 31, 2025, with an ultimate completion date of January 2, 2026. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a task under...
- The Defense Logistics Agency awarded a delivery order valued at $8,504.08 to AmerisourceBergen Drug Corp for the supply of Hysingla ER 20 mg tablets (60-count units) on September 5, 2025, with an ultimate completion date of September 8, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $2,843.74 delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Hysingla ER 40 mg tablets (60-count). This contract represents a firm fixed price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of September 16, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is executed as a child contract...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,887.98 to AmerisourceBergen Drug Corp on October 30, 2025, for the supply of Hysingla ER 20 mg tablets (60-count packages). This competitively awarded, firm fixed-price delivery order is scheduled for completion by October 31, 2025, with performance at the vendor's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was applied to this award. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor based in Conshohocken, Pennsylvania, for the supply of Hysingla ER 20 mg tablets (60-count packages) under a firm fixed-price contract valued at $1,066.00. The award, issued on August 29, 2025, with an ultimate completion date of September 2, 2025, represents a non-set-aside competitive procurement. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 20, 2025, for the supply of Hysingla ER 40 mg tablets (60-count units) with a contract value of $1,306.23. This is a firm fixed price delivery order with no set-aside designation, issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The delivery is scheduled for completion by October 21, 2025,...
- This federal contract award, valued at $7,177.29, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Hysingla ER 30 mg tablets, a medication used for pain management. This contract is a delivery order and has a firm fixed price pricing type, with an ultimate completion date of January 6, 2025. The contract does not have a set-aside designation, indicating open...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to supply Hysingla ER 60 mg tablets. The Delivery Order has a firm fixed price of $1,163.38 and an ultimate completion date of July 17, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999 through December 2025, to provide a comprehensive range of...
- This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,070.48 firm fixed-price delivery order is for the supply of HYSINGLA ER 20 MG TABLET 60S, a prescription medication. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
- This is a firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation and a leading global pharmaceutical distributor. The contract, valued at $1,163.38, is for the delivery of HYSINGLA ER 60 MG TABLET 60S, a specialty pharmaceutical product. This order falls under a larger $999,999,999.00 indefinite delivery contract that AmerisourceBergen Drug Corp holds with DLA to provide a...
- SPE2DR25D2212Indefinite Delivery Contract
- SPE2DR25D2212-SPE2DR26FB9PLDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on January 5, 2026, for the supply of Hysingla ER 30 mg tablets (60-count packages) with a ceiling value of $1,915.14. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procurement procedures. The contract is scheduled for completion by January 6, 2026, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Hysingla ER is an extended-release opioid pain medication used in military and federal healthcare systems. This delivery order is executed under AmerisourceBergen's Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen maintains an extensive portfolio of brand-name and generic medications, vaccines, and medical supplies serving Defense Health Agency, the U.S. Coast Guard, and other federal healthcare systems. The company's consistent receipt of non-set-aside, competitively awarded delivery orders demonstrates its established capability to meet federal pharmaceutical supply requirements across multiple therapeutic domains and customer bases.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 1/4/26 |